The Technology Behind Catheter-Based Interventions for Pulmonary Embolism
Introduction
Pulmonary embolism (PE) represents a significant cardiovascular challenge, ranking as a leading cause of cardiovascular-related deaths globally [1]. It occurs when a blood clot, often originating from deep vein thrombosis (DVT) in the legs, travels to the lungs and obstructs pulmonary arteries. The severity of PE can range from asymptomatic cases to life-threatening scenarios, with high-risk patients experiencing hemodynamic instability requiring immediate intervention to restore blood flow and alleviate strain on the right ventricle (RV) [1, 2]. While anticoagulation remains the cornerstone of PE management, catheter-based interventions have emerged as a promising alternative and adjunctive therapy, particularly for patients at intermediate-high risk or those with contraindications to systemic thrombolysis [1, 3]. These minimally invasive techniques aim to reduce clot burden, improve pulmonary perfusion, and stabilize hemodynamics with potentially lower bleeding risks compared to traditional systemic thrombolysis [1]. This article delves into the technological advancements driving catheter-based interventions for PE, exploring various approaches, devices, procedural considerations, and their evolving role in patient management.
Understanding Pulmonary Embolism and the Need for Intervention
Effective management of PE hinges on accurate risk stratification. The European Society of Cardiology (ESC) guidelines classify PE into high, intermediate, and low-risk categories based on clinical status, hemodynamic findings, right ventricular dysfunction (RVD), and cardiac biomarker levels [1]. High-risk PE, characterized by circulatory compromise, necessitates immediate reperfusion. Intermediate-high-risk (IHR) PE patients, though hemodynamically stable, exhibit signs of RVD and elevated cardiac biomarkers, placing them at a significant risk of clinical deterioration [1]. For these patients, timely intervention is crucial to prevent progression to cardiogenic shock and improve long-term outcomes [1].
Traditional treatments include systemic thrombolysis, which carries a considerable risk of major bleeding, and surgical embolectomy, which is highly invasive and less widely available [3]. The limitations and risks associated with these conventional methods have spurred the development of catheter-based therapies, offering targeted clot removal with potentially enhanced safety profiles.
Technologies in Catheter-Directed Therapy for PE
Catheter-directed therapies (CDT) for PE can be broadly categorized into three main approaches based on their mechanism of thrombus removal: catheter-directed thrombolysis, mechanical thrombectomy, and pharmaco-mechanical thrombectomy [1, 3]. These interventions aim to restore pulmonary blood flow, reduce RV afterload, and improve RV function.
1. Catheter-Directed Thrombolysis (CDT)
CDT involves the local delivery of thrombolytic agents directly into the pulmonary artery thrombus. This targeted approach allows for significantly lower doses of thrombolytics compared to systemic administration, thereby reducing the risk of systemic bleeding complications [1, 3].
**Standard Catheter-Directed Thrombolysis:** This method utilizes multi-perforated catheters (e.g., pigtail, Uni-Fuse by AngioDynamics, Cragg-McNamara by Medtronic) to infuse thrombolytic drugs directly into the clot [1].
**Ultrasound-Assisted Thrombolysis (USAT):** USAT, notably exemplified by the EKOS™ Endovascular System (Boston Scientific), combines low-power ultrasound energy with thrombolytic infusion. The ultrasound waves are believed to disrupt fibrin strands within the clot, enhancing the penetration and efficacy of the thrombolytic agent [1, 3]. Clinical trials such as ULTIMA, SEATTLE II, OPTALYSE PE, and the KNOCOUT PE registry have demonstrated the effectiveness of the EKOS system in reducing RV/LV ratios with a low incidence of major bleeding events [1]. While infusion durations can extend up to 24 hours, USAT offers a safe and effective option for hemodynamically stable patients without contraindications to thrombolytics.
2. Mechanical Thrombectomy
Mechanical thrombectomy techniques physically remove the thrombus through aspiration or fragmentation, offering immediate clot burden reduction without or with minimal use of thrombolytic drugs. This approach is particularly beneficial for patients with contraindications to thrombolysis or those requiring rapid hemodynamic stabilization [1, 3].
**FlowTriever® System (Inari Medical):** The FlowTriever system is a large-bore aspiration thrombectomy device designed for rapid thrombus removal. It consists of nested aspiration catheters (16 Fr, 20 Fr, and 24 Fr) and a mechanical clot-disruption tip. The FLARE trial, a prospective multicenter study, demonstrated significant improvements in RV/LV ratio and pulmonary artery pressures in IHR PE patients treated with FlowTriever, with a low rate of major bleeding [1]. The FLASH registry further supported these positive outcomes, showing rapid hemodynamic improvement and low mortality [1]. A key advantage is the ability to return aspirated blood to the patient, minimizing blood loss.
**Indigo® System (Penumbra):** The Indigo system employs aspiration catheters (7 Fr, 12 Fr, and 16 Fr) powered by a suction pump, often incorporating a separator wire to aid in clot extraction. Studies like EXTRACT-PE have shown the Indigo system's effectiveness in reducing RV/LV ratios and improving RV strain [1]. Newer generations of the Indigo system feature automated, blood-sparing capabilities. The ongoing STRIKE-PE trial continues to evaluate its efficacy and safety, with early results indicating significant reductions in RV/LV ratio and pulmonary pressures [1].
3. Pharmaco-Mechanical Thrombectomy
This approach combines the benefits of both localized thrombolysis and mechanical thrombectomy. It involves the simultaneous or sequential use of thrombolytic agents and mechanical devices to achieve more effective clot removal and improve outcomes [1]. The PEERLESS trial, a multicenter randomized controlled trial, compared large-bore mechanical thrombectomy (LBMT) with catheter-directed thrombolysis in IHR PE patients. LBMT significantly outperformed thrombolysis in reducing bailout therapies and ICU admissions, with similar mortality and major bleeding rates [1].
Procedural Planning and Considerations
Optimal procedural planning is crucial for successful catheter-based interventions. This involves a comprehensive assessment of the patient's clinical presentation, hemodynamic status, and detailed imaging to evaluate risk, locate the thrombus, and identify anatomical challenges [3].
**Risk Assessment and Thrombus Localization:** Pre-procedural imaging, including transthoracic echocardiogram (TTE) and computed tomography pulmonary angiography (CTPA), provides critical insights into RVD, thrombus location, and potential anatomical variations [3]. CTPA is particularly valuable for detailed thrombus characterization and guiding catheter navigation. Right heart catheterization is instrumental in assessing pre- and post-procedural hemodynamic status [3].
**Device Selection:** The choice between CDT and mechanical thrombectomy often depends on the patient's clinical presentation, thrombus characteristics (e.g., fresh vs. chronic), bleeding risk, and institutional expertise [3]. Mechanical thrombectomy is often preferred for hemodynamically unstable patients or those with contraindications to thrombolysis due to its ability to provide rapid clot removal [1, 3].
Potential Complications
While generally safer than systemic thrombolysis, catheter-based interventions are not without risks. Potential complications include sudden hemodynamic collapse due to thrombus fragmentation, increased RV strain from catheter manipulation, vascular injury, and bleeding [3]. Meticulous procedural technique and careful patient selection are essential to minimize these risks.
Conclusion
Catheter-based interventions have revolutionized the treatment landscape for pulmonary embolism, offering targeted and effective options for patients at varying risk levels. The continuous evolution of technologies, from ultrasound-assisted thrombolysis to advanced mechanical thrombectomy devices, provides clinicians with a growing armamentarium to address this complex condition. While anticoagulation remains foundational, CDT offers a vital alternative, particularly for high-risk and intermediate-high-risk patients. Multidisciplinary Pulmonary Embolism Response Teams (PERTs) play a crucial role in optimizing patient selection and tailoring treatment strategies, ultimately leading to improved outcomes for individuals suffering from PE [1]. Continued research and randomized controlled trials are essential to further refine these technologies and establish optimal treatment algorithms.
**Disclaimer:** This blog post is intended for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition.
References
1. Latsios, G., et al. (2025). Role of catheter-based interventions in treating pulmonary embolism. *World J Cardiol*, 17(10): 111598. [https://pmc.ncbi.nlm.nih.gov/articles/PMC12576570/](https://pmc.ncbi.nlm.nih.gov/articles/PMC12576570/) 2. Konstantinides, S. V., et al. (2019). 2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS). *Eur Heart J*, 41(5): 543–603. 3. Costa, F., et al. (2025). Catheter-based techniques for pulmonary embolism treatment. *EuroIntervention*. [https://eurointervention.pcronline.com/article/catheter-based-techniques-for-pulmonary-embolism-treatment](https://eurointervention.pcronline.com/article/catheter-based-techniques-for-pulmonary-embolism-treatment)